IN-1130 (10, 20 mg/kg/day; IP; for 7 and 14 days) reduces the extent of interstitial nephritis and fibrosis (arrowheads) with 10 mg/kg and significantly reduces or absent histopathological changes with 20 mg/kg in unilateral ureteral obstruction (UUO) rats[1].
?
IN-1130 (10, 20 mg/kg/day; for 14 days) dose-dependently decreases levels of TGF-β1 mRNA and suppresses phosphorylation of Smad2, α-SMA, myofibroblasts in rat UUO kidneys[1].
?
IN-1130 (40 mg/kg; IP; 3 times per week for 3 weeks) inhibits in vivo breast cancer metastasis to the lungs in MMTV/c-Neu mice (Eight-week-old female BALB/c mice)[2].
| Animal Model: | Six-week-old male Sprague–Dawley rats weighing 180-200 g[1] |
| Dosage: | 10 and 20 mg/kg |
| Administration: | IP; daily; for 7 and 14 days |
| Result: | Reduced the extent of interstitial nephritis and fibrosis (arrowheads) with 10 mg/kg.
|
